When one considers the many types of cardiovascular events and the many causes of death in patients with suspected or known to have coronary artery disease (Tables 1, 2) , one must marvel at how well myocardial perfusion imaging (MPI) with single-photon emission computed tomography (SPECT) and positron emission tomography (PET) have performed in predicting major adverse cardiac events (MACE). 1 Predicting death and its timing is not easy and likely could not be done perfectly solely on the basis of the myocardial perfusion pattern, myocardial blood flow (MBF), left ventricular (LV) ejection fraction (EF), innervation, or even all of these combined. 1, 2 For that reason, many studies have incorporated additional pieces of information such as demographic, socioeconomic, psychosocial, environmental, biochemical, anatomic, and genetic factors to refine the process.
There are fewer data on the prediction of the individual endpoints of MACE and even less on the mechanisms of the associations or causations. In some ways, mixing different endpoints into combined outcomes have hindered our ability to focus on the mechanistic aspects. For example, the implications and mechanisms of cardiac death are likely entirely different from those of non-fatal myocardial infarction, coronary revascularization, and quality of life measures.
Another observation in outcome data is the paucity of data on serial imaging and the mechanisms involved in worsening or improvement and the relation of such to specific endpoints (Tables 3, 4 , 5, 6, 7, 8, 9, 10) . 3 In this issue of the Journal, there is one report on MPI serial imaging. 4 Comparison of two sets of images performed at two different time intervals is inherently complicated by the fact that the changes in myocardial perfusion or MBF are not only the result of the specific intervention (for example statin therapy) but are also influenced by biological variability and by the precision and accuracy of the method used. 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Visual methods might be accurate but not reproducible, and automated methods might be reproducible but not precise. 20, 21 A common practice is to compare patient data to a normal database, but alternative methods are available that compare the two sets of images to each other directly rather than comparing each to a normal database. Such an approach may improve the detection of smaller interval changes (improvement or worsening) since the intra-patient variation is expected to be smaller than the inter-patient variation. [5] [6] [7] [8] [9] [10] Given the fact that we have had more than four decades of experience in nuclear cardiac imaging (more than any other imaging modality except invasive coronary angiography!), that ischemic heart disease is a dynamic process, that the course of the disease could be altered by therapy, and that patient survival has improved over the decades, one would expect many more studies based on serial changes on imaging. It may very well be that the data are there but not reported because the analysis is not easy! It is hard to believe that repeat imaging was not performed in studies that report outcome data of more than 5 years of follow-up even in the current era of appropriate use criteria which have slowed the pace of routine serial imaging.
When considering serial images, one needs to consider the initial results (first study), the final results (second study), and the change between the first and the second studies (expressed either as absolute or relative) ( Table 9) . 3 Consider for example 2 patients: in patient A the defect size (or MPF) decreased from 50% on initial study to 30% on follow-up study (a 20% absolute or 40% relative decrease). In patient B, the defect size increases from 10% on initial study to 20% on follow-up study (a 10% absolute and 100% relative increase). While patient A had improvement and patient B worsening, the residual abnormality is still larger in patient A than B (30% vs 20%). In addition, interpreting the change may even be more complex than this in specific patients. For example, it is possible that perfusion pattern (or MBF) improves in one vascular territory but worsens in another territory with a net effect of no MBF, myocardial blood flow; LVEF, left ventricular ejection fraction; MI, myocardial infarction, HF, heart failure, MR, mitral regurgitation, PHT, pulmonary hypertension, VT, ventricular tachycardia; VF, ventricular fibrillation * Size of MI is variable, e.g., a large MI that involves the entire anterior wall is likely different from a small rise in highsensitivity troponin that is not associated with a change in other markers # With soft endpoints, there is regional and subjective variability in rate of events, and the issue of appropriateness of the event should be considered change in the total abnormality. Although this is an extreme example, opposing changes in perfusion pattern in different vascular territories are not uncommon and it is hard to account for these changes in outcome studies (Table 5) . Finally, the perfusion changes seen on the serial studies may reflect MBF changes in culprit zone as well as the normal (control) zone (Figure 1 ; Tables 7,  8 ). Here may lay the problem of how best to model complex changes in outcome prediction. Perfusion is compared to a normal database. In addition to global information (similar to SSS/SDS/ SRS), polar maps provide information on location. Require reader supervision 7. Automated paired analysis whereby the 2 studies are compared to each other rather than to a normal database. Very attractive as the intra-patient differences might be smaller than inter-patient differences and hence smaller changes are detected SSS, summed stress score; SRS, summed rest score; SDS, summed difference score * Preferred method Table 7 . Reasons for worsening of reversible perfusion defect in serial studies 1. Artifact 2. A decrease in peak flow in culprit vessel in study 2 compared to study 1, assuming that peak flow in control zone is unchanged 3. An improvement in peak flow in normal (control) zone in study 2 compared to study 1, assuming that the peak flow in culprit zone is unchanged Table 8 . Reasons for improvement in reversible perfusion defect in serial studies 1. Artifact 2. An improvement in peak flow in culprit zone in study 2 compared to study 1, assuming that peak flow in control zone is unchanged 3. A decrease in peak flow in normal (control) zone in study 2 compared to study 1, assuming that peak flow in culprit zone is unchanged The table shows an example of improvement based on SSS, but the same concept can be used for other parameters listed in Table 3 LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; SSS, summed stress score Hopefully, our message may in a small way pave the way for more reports. Specifically, there is a need to define the best methods to evaluate changes observed on serial imaging and how to use the data in patient management and predicting different outcome endpoints. Many of the issues summarized are not limited to MPI and may be equally pertinent to other imaging modalities. Table 10 . Practical considerations for serial testing 1 . It is easier to compare 2 studies when both are normal and of good quality 2. It is easier to compare 2 studies when one is normal and the other is abnormal 3. It is more difficult to compare 2 studies when any one of the 4 image sets (2 stress and 2 rest) is of poor quality 4. It is more difficult to compare 2 studies when there are mixed fixed and reversible defects on both studies 5. Improvement in resting perfusion may be observed, which suggests that not all fixed defects are due to scar 6. The report should detail the change in perfusion in a meaningful way. This is often not easy, within the constraints of templates, used for reporting a single study. Creativity is important to personalized reporting. A phone call to the referring physician is often useful when the changes are complex
